Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000255226 | SCV000321697 | likely pathogenic | not provided | 2016-05-12 | criteria provided, single submitter | clinical testing | The V180A variant in the GALNS gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The V180A variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The V180A variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position that is conserved across species. Although in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function, missense variants in nearby residues (N177S, P179S, P179L, P179H, Y181C, E185G) have been reported in the Human Gene Mutation Database in association with mucopolysaccharidosis IVA (Stenson et al., 2014), supporting the functional importance of this region of the protein. Based on review of the data in the context of the 2015 ACMG standards and guidelines for the interpretation of sequence variants (Richards et al., 2015), we now interpret V180A as a strong candidate for a pathogenic variant. |